Refinement of strategies for the development of a human cytomegalovirus dense body vaccine.
Med Microbiol Immunol
; 197(2): 97-107, 2008 Jun.
Article
em En
| MEDLINE
| ID: mdl-18320219
Development of a vaccine against human cytomegalovirus (HCMV) infection has been identified as a high priority goal in biomedical research, yet no vaccine has been licensed until now. Recombinant subviral dense bodies (recDB) are a promising basis for the establishment of such a vaccine. In this article, strategies for the generation of recDB, based on recombination-mediated genetic engineering of the 230 kb HCMV DNA genome in E. coli are outlined. Analysis of viral mutants that were constructed in this process provided the proof-of-principle that heterologous antigens can be packaged into recDB and that these particles prime CD8 T cell responses against the recombinant antigen upon their application to HLA-A2 transgenic mice.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por Citomegalovirus
/
Vacinas contra Citomegalovirus
/
Citomegalovirus
Limite:
Animals
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article